Regeneron Pharmaceuticals Inc. (REGN) price prediction
We do not issue point price predictions. Instead, our analysis anchors REGN to a composite fair-value range of $917–$1505 (midpoint $1210, current price $715) and a probability-weighted bull/base/bear distribution that resolves to a weighted price target of $1,210.30 and a weighted return of +69.3%.
Bull, base and bear price targets
Bull case (probability 20%): target $1,505.07, implied return +110.5%. Base case (probability 60%): target $1,209.72, implied return +69.2%. Bear case (probability 20%): target $917.25, implied return +28.3%.
These are not points-on-a-chart guesses. Each scenario is built from explicit revenue, margin, and capital-allocation assumptions, and discounted at 7.61%. Probability weights are calibrated to Regeneron Pharmaceuticals Inc.'s mature compounder archetype — the bull tail is fatter for hyper-growth names, thinner for mature compounders, and inverted for cyclicals near peak.
Probability-weighted expected return
Folding bull/base/bear into a single weighted view, REGN's probability-weighted price target is $1,210.30 and the weighted return is +69.3%. The asymmetry signal — the gap between weighted return and base-case return — is Probability-weighted scenario value points to favorable asymmetry versus the current price across the bear, base, and bull paths..
Asymmetry matters more than the headline return. A 10% expected return with a 30%-bear/15%-bull dispersion is a different bet than a 10% expected return with a 10%-bear/12%-bull dispersion. The full report walks through both for REGN.
What our forecast deliberately does not do
We do not publish twelve monthly price targets across a calendar year, we do not back-test indicators on past prices, and we do not anchor any number to "analyst consensus" — the consensus is a useful sanity check, not a target. If our composite fair value differs from the analyst consensus by more than 30%, the full report runs a consensus-divergence diagnostic instead of silently revising toward the crowd.
What we do publish: the 5×5 Ke-versus-terminal-growth sensitivity matrix, five formal stress tests with quantified fair-value impact, an earnings decision tree if reporting is within 60 days, and explicit position-management checkpoints. Together those answer "what if my view is wrong?" — a more useful question for an investor than "what's the price next month?".
How to use this for REGN
Anchor on the fair-value range ($917–$1505), size against the bull/base/bear distribution, and define a kill-scenario list before entry. Our current rating for REGN is Strong Buy; rating-band changes are the trigger for re-sizing, not for trading the noise around them.
For the canonical version of this answer — including the sensitivity matrix, scorecard, and full assumption ledger — see the full report at /stocks/regn/analysis.
Frequently asked questions
What is the price prediction for REGN?
We anchor REGN to a fair-value range of $917–$1505, with a midpoint of $1210. The probability-weighted price target is $1,210.30 (weighted return +69.3%). We do not issue single-point price predictions.
What is the bull-case target for REGN?
The bull case (probability 20%) targets $1,505.07, an implied return of +110.5%.
What is the bear-case target for REGN?
The bear case (probability 20%) targets $917.25, an implied return of +28.3%.
Do you publish a 12-month REGN price target?
No. We publish a fair-value range, a bull/base/bear distribution with explicit probabilities, and a probability-weighted expected return — not a single 12-month point.
Research for educational purposes. Not personalised investment advice. See the full REGN report for the canonical evidence.